DSSG Group: Basket (multiple types)

Patients with Intact Brain Metastases for Non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma or GI Cancer.

Researchers are conducting this study to compare two different types of radiation therapy: the standard one-day treatment called Single Fraction Stereotactic Radiosurgery (SRS) and an alternative approach called Fractionated Stereotactic Radiosurgery (FSRS), which involves three treatments over about one week.

Patients diagnosed with oligometastatic cancer

The goal of the study is to determine what the side effects of single or multiple fraction Stereotactic Ablative Radiotherapy (SABR) are, and what is the most optimal treatment which could be used in future studies.

Patient with histologically-confirmed malignancy who are candidates for or planned to commence immune checkpoint inhibitor therapy for cancer (either alone or in combination with other anti-cancer treatments).

The aims of this study are to collect biospecimens (including blood, tumour tissue, +/- oral swish, stool, urine, +/-bronchoalveolar lavage/bronchial brushings) for biomarker discovery. To characterise the relationship between host microbiome, genomic and immunologic factors and disease prognosis in patients with malignancies who are receiving or due to receive immune checkpoint inhibitors. To characterise the relationship between the host microbiome, genomic and immunologic factors and treatment response and/or progression in patients with malignancies who are receiving or due to receive immune checkpoint inhibitors. To characterise the relationship between host microbiome, genomic and immunologic factors and treatment toxicities in patients with malignancies who are receiving or due to receive immune checkpoint inhibitors. To facilitate further research into potential microbiome/genomic/immunological biomarkers that may be predictive of disease prognosis, treatment response, treatment progression and immune-mediated toxicity in patients with advanced malignancies who are receiving or due to receive immune checkpoint inhibitors.

Participants 18 years or older, due to receive palliative intent radiotherapy with conventional or stereotactic body radiotherapy techniques, willing to complete questionnaires with a prognosis of at least 3 months.

The purpose of this study is to understand the impact of palliative and ablative radiotherapy (RT) treatment on HRQOL in patients with metastatic disease using the electronic patient-reported outcome platform ONCOpatient. Data will be collected at 4 timepoints: at the pre-treatment, final treatment and 4-weeks and 3 months post-treatment.

Any locally advanced or metastatic cancer with taste problems.

An investigation into taste problems associated with xerostomia (dry mouth) in patients with advanced cancer.

For older persons with cancer.

The aim of the study is to evaluate the effectiveness and cost-effectiveness of a patient and family navigation intervention (NavCare-EU) for older people with cancer and declining health and their family caregivers in different healthcare systems in Europe

Metastatic or unresectable solid tumour who are eligible to receive Immune Checkpoint Inhibitor’s(ICI’s) alone or in combination with chemotherapy.

The purpose of this study is to compare the faecal microbiome pre and post ICI treatment to look got biomarkers of positive treatment response.

All cancer types known to palliative care services.

A current or prior cancer diagnosis who have clinical insomnia.

This study will examine the efficacy of digital cognitive behavioural therapy for insomnia (dCBT-I) compared to sleep hygiene education.

Gastrointestinal (GI)/genitourinary (GU) cancer associated VTE

The purpose of this study is to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE.